"Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs
- 1 November 2003
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 59 (8), 645-649
- https://doi.org/10.1007/s00228-003-0661-8
Abstract
Non-steroidal anti inflammatory drugs (NSAIDs) are thought to account for almost 25% of all reported adverse drug reactions, primarily gastrointestinal (GI) toxicity. Selective cyclo-oxygenase-2 (COX-2) inhibitors have been shown to preferentially inhibit activity of the COX-2 enzyme, which maintains anti-inflammatory activity but reduces GI toxicity.Keywords
This publication has 11 references indexed in Scilit:
- Peptic-ulcer diseaseThe Lancet, 2002
- Drug switching patterns among patients taking non‐steroidal anti‐inflammatory drugs: a retrospective cohort study of a general practitioners database in the United KingdomPharmacoepidemiology and Drug Safety, 2001
- Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complicationsAmerican Journal Of Medicine, 1999
- Cyclooxygenase 2 selective inhibitors: Panacea or flash in the pan?Gastroenterology, 1999
- The cyclooxygenase-2 inhibitors: safety and effectiveness.Annals of Pharmacotherapy, 1999
- Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1999
- The Influence of Hospital-Based Prescribers on Prescribing in General PracticePharmacoEconomics, 1999
- Effect of the British warning on contraceptive use in the General Medical Service in Ireland.1998
- Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugsThe Lancet, 1994
- Patterns of interchange in the dispensing of non-steroidal anti-inflammatory drugsJournal of Clinical Epidemiology, 1992